"Thrombocytopenia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subnormal level of BLOOD PLATELETS.
Descriptor ID |
D013921
|
MeSH Number(s) |
C15.378.140.855
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Thrombocytopenia".
Below are MeSH descriptors whose meaning is more specific than "Thrombocytopenia".
This graph shows the total number of publications written about "Thrombocytopenia" by people in this website by year, and whether "Thrombocytopenia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 5 | 5 |
1995 | 0 | 3 | 3 |
1996 | 0 | 2 | 2 |
1997 | 0 | 1 | 1 |
1998 | 1 | 2 | 3 |
2000 | 0 | 2 | 2 |
2001 | 0 | 2 | 2 |
2002 | 2 | 2 | 4 |
2003 | 0 | 3 | 3 |
2004 | 0 | 3 | 3 |
2005 | 2 | 1 | 3 |
2006 | 2 | 2 | 4 |
2007 | 0 | 4 | 4 |
2008 | 1 | 0 | 1 |
2009 | 1 | 4 | 5 |
2010 | 1 | 1 | 2 |
2011 | 0 | 1 | 1 |
2012 | 1 | 1 | 2 |
2013 | 0 | 2 | 2 |
2014 | 1 | 2 | 3 |
2015 | 2 | 1 | 3 |
2016 | 1 | 3 | 4 |
2017 | 2 | 2 | 4 |
2018 | 2 | 2 | 4 |
2019 | 0 | 1 | 1 |
2020 | 6 | 4 | 10 |
2021 | 8 | 3 | 11 |
2022 | 6 | 0 | 6 |
2023 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Thrombocytopenia" by people in Profiles.
-
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study. Lancet Oncol. 2024 Jan; 25(1):29-45.
-
SERUM HUMANIN IN PEDIATRIC SEPTIC SHOCK-ASSOCIATED MULTIPLE-ORGAN DYSFUNCTION SYNDROME. Shock. 2024 Jan 01; 61(1):83-88.
-
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023 Oct; 10(10):e825-e837.
-
Treatment of thrombocytopenia and thrombosis in HIT in mice using deglycosylated KKO: a novel therapeutic? Blood Adv. 2023 08 08; 7(15):4112-4123.
-
Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study. Lancet Haematol. 2023 Apr; 10(4):e272-e283.
-
Off-the-shelf cryopreserved platelets for the detection of HIT and VITT antibodies. Blood. 2022 12 22; 140(25):2722-2729.
-
Ancestry, ACKR1 and leucopenia in patients with systemic lupus erythematosus. Lupus Sci Med. 2022 11; 9(1).
-
Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022 08; 23(8):1066-1077.
-
Lurbinectedin-induced thrombocytopenia: the role of body surface area. Cancer Chemother Pharmacol. 2022 05; 89(5):573-575.
-
Persistence of Ad26.COV2.S-associated vaccine-induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies. Am J Hematol. 2022 05; 97(5):519-526.